QUANTUM X LABS INC. quarterly report, Q2 FY2009

SEC Filing Summary: Zaxis International Inc. (10-Q)

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2009, for Zaxis International Inc. (Note: The input metadata referenced "Quantum X Labs Inc.", but the filing text explicitly identifies the registrant as Zaxis International Inc.). The Company is a "shell company" with no present operations. Following a Chapter 7 bankruptcy in 2002 and emergence in 2004, the Company ceased its former biotechnology operations. Current management is directing limited resources solely toward identifying and effecting a business combination (acquisition or merger) with a target company.

Key Financial Metrics

Metric Six Months Ended June 30, 2009 Three Months Ended June 30, 2009 As of June 30, 2009
Revenue $0 $0 N/A
Net Loss $(23,488) $(9,729) N/A
Cash Balance N/A N/A $0
Total Assets N/A N/A $0
Total Current Liabilities N/A N/A $112,855
Stockholders' Deficiency N/A N/A $(112,855)
Shares Outstanding N/A N/A 1,073,126

Note: The filing does not provide data for gross margins or operating margins as there is no revenue. Liquidity is critically constrained with zero cash on hand.

Material Changes vs. Prior Period

  • Cash Position: Cash decreased from $119 at December 31, 2008, to $0 at June 30, 2009.
  • Liabilities: Total current liabilities increased from $91,655 to $112,855, driven primarily by an increase in "Advances from and accruals due to related parties" (from $89,655 to $108,355).
  • Net Loss: The net loss for the six-month period increased to $(23,488) compared to $(21,064) in the same period of 2008.
  • Financing Activity: The Company received $700 in advances from related parties during the six-month period ended June 30, 2009, compared to $35 in the prior year period.

Outlook, Risks, and Management Commentary

Plan of Operation: Management intends to pursue a business combination to acquire an operating company. No specific target industry or business has been identified. The Company anticipates using its status as a public entity to facilitate acquisitions that might otherwise face difficulties in traditional IPOs.

Liquidity Risks: The Company has no assets and relies on advances from related parties to fund minimal administrative expenses. There is no assurance that additional equity or debt financing will be available to fund a business combination. Failure to secure funding could result in the inability to complete a transaction.

Key Risks:

  • Shell Company Status: Investors are investing in a shell company with no operating history or assets; success depends entirely on a future acquisition.
  • Lack of Diversification: The Company likely lacks resources to diversify, making it dependent on the performance of a single future business.
  • Dilution: Effecting a business combination will likely involve issuing a substantial number of restricted shares, causing significant dilution to existing shareholders.
  • Management Experience: There is no assurance that future management of a target company will have the skills to manage a public company.

Investor Verification Checklist

  • Verify Identity: Confirm the registrant is Zaxis International Inc., not "Quantum X Labs Inc." as suggested in external metadata.
  • Assess Solvency: Review the $112,855 in related-party liabilities and zero cash balance to understand the immediate risk of insolvency.
  • Monitor Related Party Transactions: Track the increasing reliance on advances from related parties ($700 in the last six months) as the primary funding source.
  • Check for Target Announcements: Verify if any specific acquisition targets have been identified since the filing date, as none were listed in this report.
  • Review Stock Dilution Terms: Understand that any future business combination will likely require issuing new shares, significantly diluting current ownership.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.